


Amendments to the Claims

1. (Cancelled)
2. (Cancelled)
3. (Cancelled)
4. (Cancelled)
5. (Cancelled)
6. (Cancelled)
7. (Cancelled)
8. (Cancelled)
9. (Previously Amended) A cyclic peptide having the structure:



wherein Xaa is Tyr or Ala.

10. (Cancelled)
11. (Previously Amended) A peptide of claim 9, wherein Xaa is Tyr (SEQ ID NO:10).
12. (Previously Presented) The cyclic peptide of claim 9, wherein the cyclic peptide is in contact with an aqueous solution.

13. (Cancelled)

14. (Cancelled)

15. (Cancelled)

16. (Cancelled)


17. (Cancelled)

18. (Cancelled)

19. (Cancelled)

20. (Currently Amended) A method of identifying or designing a phospholamban deactivator, comprising the steps of:

(a) obtaining a three dimensional structure of a cyclic peptide



wherein Xaa is Tyr or Ala;

(b) creating a three dimensional model of a complex of the cyclic peptide bound as a phospholamban deactivator to the phospholamban cytosolic domain of phospholamban or a ~~portion~~ fragment of the phospholamban cytosolic domain that ~~allows binding of the phospholamban deactivator to phospholamban~~ comprises a ligand binding site;

(c) employing the three dimensional model of the complex to identify [a] the ligand binding site on the phospholamban cytosolic domain or on said ~~portion~~ fragment of the phospholamban cytosolic domain, wherein ~~the ligand binding site is a site at which~~ the phospholamban deactivator binds to the phospholamban cytosolic domain or to said ~~portion~~ fragment of the phospholamban cytosolic domain ~~when the phospholamban deactivator is bound to phospholamban at said ligand binding site;~~

(d) selecting a candidate molecule that possesses steric and electrostatic complementarity with the ligand binding site and testing same for function as a phospholamban deactivator; and

(e) identifying the selected candidate molecule as a ~~potential~~ phospholamban deactivator, ~~wherein the potential phospholamban deactivator can be subsequently synthesized and tested for its ability to function as the phospholamban deactivator.~~

21. (Currently Amended) The method of claim 20, ~~which further~~ wherein step (d) comprises:

[(f)] synthesizing ~~the potential phospholamban deactivator~~ and testing the ~~synthesized potential~~ phospholamban deactivator for activation of CaATPase Ca⁺²-ATPase in the presence of phospholamban.

22. (Previously Presented) The method of claim 20, wherein step (a) comprises obtaining a first set of atom coordinates defining the three dimensional structure of the cyclic peptide.

23. (Currently Amended) The method of claim 20, wherein step (b) comprises:

- (i) obtaining [the] a first set of atom coordinates defining the three dimensional structure of the cyclic peptide of step (a);
- (ii) obtaining a second set of atom coordinates defining the phospholamban cytosolic domain or said ~~portion~~ fragment of the phospholamban cytosolic domain; and
- (iii) employing a computer-aided molecular modeling program to combine the first set of atom coordinates with the second set of atom coordinates to create a three dimensional model of a complex of the cyclic peptide bound to phospholamban cytosolic domain or said ~~portion~~ fragment of the phospholamban cytosolic domain.

24. (Currently Amended) The method of claim 20, wherein step (c) employs a computer-aided molecular modeling program to identify the ligand binding site on the phospholamban cytosolic domain or said ~~portion~~ fragment of the phospholamban cytosolic domain.

25. (Currently Amended) The method of claim 20, wherein step (d) employs a computer-aided molecular modeling program to identify the ~~compound capable of interacting~~ molecule that interacts with the ligand binding site of the phospholamban cytosolic domain or said ~~portion~~ fragment of the phospholamban cytosolic domain thereof.

26. (Currently Amended) The method of claim 20, wherein step (d) comprises:

- (i') providing atom coordinates defining a three-dimensional structure of the phospholamban cytosolic domain or said ~~portion~~ fragment of the phospholamban

cytosolic domain that is in a conformation which allows binding of the phospholamban deactivator;

(ii') combining the atom coordinates defining the three-dimensional structure of the phospholamban cytosolic domain or said ~~portion~~ fragment of the phospholamban cytosolic domain of step (i') with a set of atom coordinates defining a three dimensional structure of a candidate molecule;

(iii') employing a computer-aided molecular modeling program, with the atom coordinates defining the three-dimensional structure of the phospholamban cytosolic domain or said ~~portion~~ fragment of the phospholamban cytosolic domain and the atom coordinates defining the three dimensional structure of the candidate molecule, to evaluate the ability of the candidate molecule to bind to the ligand binding site of the phospholamban cytosolic domain or said ~~portion~~ fragment of the phospholamban cytosolic domain; and

(iv') selecting the candidate molecule that interacts favorably with the ligand binding site of the phospholamban cytosolic domain or said ~~portion~~ fragment of the phospholamban cytosolic domain, or that possesses steric and electrostatic complementarity with the ligand binding site.

27. (Currently Amended) The method of claim 26, wherein the atom coordinates defining the three-dimensional structure of the phospholamban cytosolic domain or said ~~portion~~ fragment of the phospholamban cytosolic domain are obtained from the three dimensional model of the complex created in step (b).

28. (Currently Amended) The method of claim 26, wherein step (iii') comprises:

(iiia') performing a fitting operation between the candidate molecule and the ligand binding site of the phospholamban cytosolic domain or said ~~portion~~ fragment of the phospholamban cytosolic domain; and

(iiib') analyzing the results of the fitting operation to quantify association between the candidate molecule and the ligand binding site of the phospholamban cytosolic domain or said ~~portion~~ fragment of the phospholamban cytosolic domain.

29. (Currently Amended) The method of claim 26, wherein step (iii') comprises:


(iiia'') displaying in a graphical format a protein structure encoded by the combination of the atom coordinates defining the three-dimensional structure of the phospholamban cytosolic domain or said ~~portion~~ fragment of the phospholamban cytosolic domain and the atom coordinates defining the three dimensional structure of the candidate molecule; and

(iiib'') visually inspecting the protein structure displayed in the graphical format to evaluate the ability of the candidate molecule to bind to the ligand binding site of the phospholamban cytosolic domain or said ~~portion~~ fragment of the phospholamban cytosolic domain.

30. (Previously Presented) The method of claim 20, wherein Xaa of the cyclic peptide is Tyr (SEQ ID NO:10).

31. (Currently Amended) A method of identifying a target area on the surface of phospholamban, at which a phospholamban deactivator binds, the method comprising the steps of:

- (a) obtaining a three dimensional structure of a cyclic peptide



wherein Xaa is Tyr or Ala;

- (b) creating a three dimensional model of a complex of the cyclic peptide as a phospholamban deactivator bound to phospholamban cytosolic domain or a portion fragment of the phospholamban cytosolic domain that ~~allows binding of a phospholamban deactivator to phospholamban~~ comprises a ligand binding site; and

- (c) employing a computer-aided molecular modeling program and the three dimensional model of the complex to identify the target area on the surface of phospholamban, wherein ~~said target area is the site at which~~ said phospholamban deactivator binds to the phospholamban cytosolic domain or to said ~~portion~~ fragment of the phospholamban cytosolic domain ~~when said phospholamban deactivator is bound to phospholamban~~ at said ligand binding site.

32. (Previously Presented) The method of claim 31, wherein Xaa of the cyclic peptide is Tyr (SEQ ID NO:10).

33. (Withdrawn) A method of preventing inhibition exerted by phospholamban on CaATPase in a cardiac cell, comprising introducing the cyclic peptide of claim 9 into a cardiac cell.